1. Home
  2. AZTR vs GOVX Comparison

AZTR vs GOVX Comparison

Compare AZTR & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.14

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.79

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZTR
GOVX
Founded
2014
2001
Country
United States
United States
Employees
N/A
19
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.8M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
AZTR
GOVX
Price
$0.14
$0.79
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$4.00
$1.00
AVG Volume (30 Days)
901.1K
201.0K
Earning Date
05-08-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
5.06
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.12
52 Week High
$1.40
$4.40

Technical Indicators

Market Signals
Indicator
AZTR
GOVX
Relative Strength Index (RSI) 42.61 40.41
Support Level $0.12 $0.64
Resistance Level $0.15 $2.00
Average True Range (ATR) 0.01 0.09
MACD 0.00 0.02
Stochastic Oscillator 49.30 40.98

Price Performance

Historical Comparison
AZTR
GOVX

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: